BBOT to Participate in Upcoming September Investor Healthcare Conferences
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), a clinical-stage biopharmaceutical company specializing in RAS-pathway malignancies, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference on September 4 at 8:35 a.m. ET and the Morgan Stanley Global Healthcare Conference on September 8 at 7:45 a.m. ET. Both events will include fireside chats and investor meetings in New York. Webcasts and replays will be accessible through BBOT's investor relations website for 90 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction – BBOT
In the Aug 20 session, BBOT declined 5.59%, reflecting a notable negative market reaction. Argus tracked a peak move of +16.4% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.
Details of the company’s participation are as follows:
- Cantor Global Healthcare Conference
- Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York
- Morgan Stanley Global Healthcare Conference
- Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York
Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Uneek Mehra, Chief Financial Officer
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
